ValiRx (LSE:VAL) Net Margin %

: 0.00% (As of Jun. 2023)

View and export this data going back to 2000. Start your Free Trial

Net margin is calculated as Net Income divided by its Revenue. ValiRx's Net Income for the six months ended in Jun. 2023 was £-1.04 Mil. ValiRx's Revenue for the six months ended in Jun. 2023 was £0.00 Mil. Therefore, ValiRx's net margin for the quarter that ended in Jun. 2023 was 0.00%.

The historical rank and industry rank for ValiRx's Net Margin % or its related term are showing as below:

LSE:VAL's Net Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: -164.06
* Ranked among companies with meaningful Net Margin % only.

ValiRx Net Margin % Historical Data

The historical data trend for ValiRx's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ValiRx Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Net Margin %

ValiRx Semi-Annual Data
	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Net Margin %																-	-	-	-	-

Competitive Comparison

For the Biotechnology subindustry, ValiRx's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ValiRx Net Margin % Distribution

For the Biotechnology industry and Healthcare sector, ValiRx's Net Margin % distribution charts can be found below:

* The bar in red indicates where ValiRx's Net Margin % falls into.

ValiRx Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

ValiRx's Net Margin for the fiscal year that ended in Dec. 2022 is calculated as

Net Margin	=	Net Income (A: Dec. 2022 )	/	Revenue (A: Dec. 2022 )
	=	-2.366	/	0
	=	%

ValiRx's Net Margin for the quarter that ended in Jun. 2023 is calculated as

Net Margin	=	Net Income (Q: Jun. 2023 )	/	Revenue (Q: Jun. 2023 )
	=	-1.035	/	0
	=	%

ValiRx (LSE:VAL) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

ValiRx Net Margin % Related Terms

Thank you for viewing the detailed overview of ValiRx's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

ValiRx (LSE:VAL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ValiRx PLC (LSE:VAL) » Definitions » Net Margin %

Comparable Companies

Traded in Other Exchanges

EAJF:Germany

Address

4 Barling Way, Eliot Park Innovation Centre, Nuneaton, GBR, CV10 7RH

Website

https://www.valirx.com

ValiRx PLC is a UK-based biopharmaceutical company. It mainly engages in developing technologies and products in oncology therapeutics and diagnostics. The area of focus for the company is the treatment of cancer and associated biomarkers, specializing in epigenomic and genetic analysis. The company develops therapeutics across fields in oncology and has a portfolio of products in the pipeline which include GeneICE for Silencing Rebellious Genes, VAL201 for prostate cancer, NAV3 for the cancer screening test, and VAL401 for lung cancer.